Edition:
India

Tabula Rasa HealthCare Inc (TRHC.OQ)

TRHC.OQ on NASDAQ Stock Exchange Global Market

34.54USD
17 Nov 2017
Change (% chg)

$-0.12 (-0.35%)
Prev Close
$34.66
Open
$34.65
Day's High
$35.07
Day's Low
$33.86
Volume
49,385
Avg. Vol
38,394
52-wk High
$35.07
52-wk Low
$10.63

Chart for

About

Tabula Rasa HealthCare, Inc. (Tabula Rasa), formerly CareKinesis, Inc., is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a... (more)

Overall

Beta: --
Market Cap(Mil.): $479.66
Shares Outstanding(Mil.): 17.36
Dividend: --
Yield (%): --

Financials

BRIEF-Tabula rasa posts Q3 EPS of $0.41

* Tabula rasa healthcare announces third quarter 2017 results

07 Nov 2017

BRIEF-Tabula Rasa - files for mixed shelf offering of up to $200 mln

* Tabula Rasa Healthcare Inc - files for mixed shelf offering of up to $200 million - SEC filing‍​

16 Oct 2017

BRIEF-Tabula Rasa Healthcare paid $35 mln to Sinfonía Healthcare after merger

* Tabula Rasa Healthcare Inc - ‍ at closing of merger with Sinfonía Healthcare Corporation​, TRHC paid $35 million in cash consideration - SEC filing

07 Sep 2017

BRIEF-Tabula rasa healthcare acquires SinfoníaRx expanding its medication therapy management offering

* Tabula Rasa Healthcare acquires SinfoníaRx expanding its medication therapy management offering

07 Sep 2017

BRIEF-Tabula Rasa HealthCare's PACE division signs agreement with CenterLight Healthcare PACE

* Tabula Rasa HealthCare’s PACE division signs agreement with CenterLight Healthcare PACE to manage medication risk, improve quality and outcomes

29 Aug 2017

BRIEF-Tabula Rasa Healthcare posts Q2 loss per share $0.09

* Tabula Rasa Healthcare announces second quarter 2017 results

08 Aug 2017

BRIEF-Tabula Rasa Healthcare reports Q2 loss per share of $0.09

* Tabula Rasa Healthcare announces second quarter 2017 results

08 Aug 2017

Earnings vs. Estimates